Antifungal prophylaxis: why, what and how? - Wikidata - awgldk - TriplyDB

Antifungal prophylaxis: why, what and how?

Antifungal prophylaxis: why, what and how?

http://www.wikidata.org/entity/Q45897793

about

Antifungal prophylaxis: why, what and how?

http://www.wikidata.org/entity/Q45897793

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年学术文章

@wuu

2015年学术文章

@zh

2015年学术文章

@zh-cn

2015年学术文章

@zh-hans

2015年学术文章

@zh-my

2015年学术文章

@zh-sg

2015年學術文章

@yue

2015年學術文章

@zh-hant

name

Antifungal prophylaxis: why, what and how?

@en

Antifungal prophylaxis: why, what and how?

@nl

type

label

Antifungal prophylaxis: why, what and how?

@en

Antifungal prophylaxis: why, what and how?

@nl

prefLabel

Antifungal prophylaxis: why, what and how?

@en

Antifungal prophylaxis: why, what and how?

@nl

P1433

Q45897793-A98BF2B4-54A0-4F35-AA62-5F3F584E567E

P1476

Q45897793-907572E8-74A0-4060-8F3C-6EFFDB407E57

P2860

Q45897793-24A17052-E887-4A71-BD78-BD9CACEE5D5C

Q45897793-38604845-6B87-4E6E-9CFD-A763A4D872A2

Q45897793-6FF9D63E-C582-4BDD-ACCA-698F8CD76620

Q45897793-703880A6-CF37-41C7-BDFF-30F43D353EE1

Q45897793-7B3F5CF1-A995-4587-A6EE-D40486A77D50

Q45897793-926F2899-9411-4BE0-92B2-6EB9578A3CBA

Q45897793-C2B5D060-D4E3-4C7A-A366-FC221804844D

Q45897793-D37609B4-372A-4B58-BF4F-AF4C55C37010

Q45897793-E4378CBE-04C9-45F6-BBC3-E6A1A9994FAF

P304

Q45897793-28E8336D-ADA1-4422-B9C1-13A51C8EDBD8

P31

Q45897793-D984423A-3451-4AE9-A23B-A5C211C3242B

P356

Q45897793-ED6428BD-7BCA-4B25-A081-6F19F72CDA31

P433

Q45897793-22844348-2EB9-476E-82A9-66428EB88668

P478

Q45897793-0C8D37C9-00F4-4B93-9467-30AB9E157125

P50

Q45897793-8FE5D84B-9ACD-4996-B3A6-A5EF689B0291

P577

Q45897793-A458EF04-0C26-48DE-ADBE-6D7F26652D70

P698

Q45897793-C0386B97-0CF6-4A13-A38C-7EDB32A276A2

P356

P1433

Future Microbiology

P1476

Antifungal prophylaxis: why, what and how?

@en

P2860

Antifungal prophylaxis in cancer patients after chemotherapy or hematopoietic stem-cell transplantation: systematic review and meta-analysis.

Invasive aspergillosis in patients with acute myeloid leukemia: a SEIFEM-2008 registry study.

Randomized, double-blind trial of fluconazole versus voriconazole for prevention of invasive fungal infection after allogeneic hematopoietic cell transplantation.

Switching from posaconazole suspension to tablets increases serum drug levels in leukemia patients without clinically relevant hepatotoxicity.

Safety and pharmacokinetics of isavuconazole as antifungal prophylaxis in acute myeloid leukemia patients with neutropenia: results of a phase 2, dose escalation study

Voriconazole versus itraconazole for antifungal prophylaxis following allogeneic haematopoietic stem-cell transplantation.

Posaconazole therapeutic drug monitoring in the real-life setting: a single-center experience and review of the literature.

Prospective surveillance for invasive fungal infections in hematopoietic stem cell transplant recipients, 2001-2006: overview of the Transplant-Associated Infection Surveillance Network (TRANSNET) Database.

Fungal infections in recipients of hematopoietic stem cell transplants: results of the SEIFEM B-2004 study--Sorveglianza Epidemiologica Infezioni Fungine Nelle Emopatie Maligne.

P304

11-15

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2217/FMB.15.129

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

11

http://www.w3.org/2001/XMLSchema#string

P50

P577

2015-12-17T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26674314

http://www.w3.org/2001/XMLSchema#string